A strategy that shows great promise for treating pancreatic cancer is to combine cytotoxic treatments with agents that abrogate the already-tenuous checkpoint functionality exhibited by most tumor cells. Drugs that target the checkpoint protein Chk1 (such as AZD7762, currently in Phase-I clinical trials) are of particular interest in the context of pancreatic cancer because Chkl has also been shown to have a critical role in mediating the activity of Rad51, a key protein in homologous recombination repair (HRR) that is associated with resistance to DNA damaging treatments, and is upregulated in human pancreatic tumors. The long term goal of our work Is to improve the outcome of patients with pancreatic cancer by rationally adding Chk1 inhibitors to the combination of Gem and radiation. Our preliminary data demonstrate that both chemo- and radiosensitization by AZD7762 vary substantially among human pancreatic tumor cell lines, and that under conditions of sensitization, AZD7762 affects several endpoints related to HRR. We also found that endpoints related to G2/M checkpoint abrogation reflected sensitization in some cases but not in others.
Specific Aim 1 is to determine the mechanisms by which AZD7762 treatment affects HRR activity and sensitivity to Gem and IR in pancreatic cancer cell lines, in vitro. This work will allow us to identify mechanism-based molecular endpoints to be interrogated in future clinical studies, and to identify new targets for therapeutic intervention, related to HRR activity. Although the mechanistic basis for therapeutic effects of Chkl inhibitors is not yet completely understood, our data in vitro and in vivo already provide strong motivation for conducting an initial clinical trial.
Specific Aim 2 is to use xenograft models to establish the basis for conducting a clinical trial combining AZD7762 with Gem and radiation. The results of Aim 2 will help to define the design of our subsequent clinical trial.
Specific Aim 3 is to carry out a clinical trial using AZD7762 in combination with Gem and radiation in patients with resected pancreatic cancer. We will use a combination of Gem and radiation followed by Gem alone, combined with dose-escalating AZD7762, based on the schedule suggested in Aim 2. We hypothesize that the MTD for AZD7762 will be similar to that detennined in the current phase I trials using Gem alone (i.e. that adding conformal radiation will have a minimal impact on the MTD of AZD7762 in combination with Gem). Also, we hypothesize that AZD7762 will inhibit Chkl activity in surrogate normal tissues when administered at the MTD, and, possibly, at lower doses.
|Triner, Daniel; Xue, Xiang; Schwartz, Andrew J et al. (2017) Epithelial Hypoxia-Inducible Factor 2? Facilitates the Progression of Colon Tumors through Recruiting Neutrophils. Mol Cell Biol 37:|
|An, Mingrui; Lohse, Ines; Tan, Zhijing et al. (2017) Quantitative Proteomic Analysis of Serum Exosomes from Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy. J Proteome Res 16:1763-1772|
|Djuric, Zora; Aslam, Muhammad Nadeem; Simon, Becky R et al. (2017) Effects of fish oil supplementation on prostaglandins in normal and tumor colon tissue: modulation by the lipogenic phenotype of colon tumors. J Nutr Biochem 46:90-99|
|Dosch, Joseph; Ziemke, Elizabeth; Wan, Shanshan et al. (2017) Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget 8:65090-65099|
|Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2017) Lymph Node Metastases in Colon Cancer are Polyclonal. Clin Cancer Res :|
|Stoffel, Elena M; Koeppe, Erika; Everett, Jessica et al. (2017) Germline Genetic Features of Young Individuals with Colorectal Cancer. Gastroenterology :|
|Djuric, Zora (2017) Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state. Transl Res 179:155-167|
|Parsels, Leslie A; Karnak, David; Parsels, Joshua D et al. (2017) PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res :|
|Demitrack, Elise S; Samuelson, Linda C (2017) Notch as a Driver of Gastric Epithelial Cell Proliferation. Cell Mol Gastroenterol Hepatol 3:323-330|
|Djuric, Zora; Aslam, Muhammad Nadeem; Simon, Becky R et al. (2017) Fatty acid and lipidomic data in normal and tumor colon tissues of rats fed diets with and without fish oil. Data Brief 13:661-666|
Showing the most recent 10 out of 95 publications